Please wait while we open this resource.
PERIOPERATIVE ATEZOLIZUMAB PLUS FLUOROURACIL, LEUCOVORIN, OXALIPLATIN, AND DOCETAXEL FOR RESECTABLE ESOPHAGOGASTRIC CANCER: INTERIM RESULTS FROM THE RANDOMIZED, MULTICENTER, PHASE II/III DANTE/IKF-S633 TRIAL — OslerMarket